
Charles N. Landen MD MS
Gynecologic Oncology
Associate Professor, Obstetrics & Gynecology, University of Virginia
Join to View Full Profile
1240 Lee StCharlottesville, VA 22908
Phone+1 434-924-5100
Fax+1 434-982-1840
Dr. Landen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Medical University of South CarolinaResidency, Obstetrics and Gynecology, 1998 - 2002
- University of North Carolina at Chapel Hill School of MedicineClass of 1998
- University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology
Certifications & Licensure
- VA State Medical License 2014 - 2026
- AL State Medical License 2009 - 2014
- TX State Medical License 2005 - 2010
- SC State Medical License 2000 - 2003
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- The potential for opportunistic salpingectomy to reduce ovarian cancer in women undergoing non-gynecologic surgery.Ian C Cook, Sarah E Podwika, Peter T Hallowell, Mark R Conaway, Charles N Landen
Gynecologic Oncology Reports. 2025-04-01 - Application of a Malecot drain in the management of a vaginal cuff dehiscence: A case report and review of the literature.Bria Murray, Caleigh E Smith, Jorge Alsina, Megan Howard, Charles Landen
Gynecologic Oncology Reports. 2024-08-01 - 4 citationsPhase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.Charles N Landen, Ronald J Buckanovich, Michael W Sill, Robert S Mannel, Joan L Walker
Journal of Clinical Oncology. 2024-07-20
Press Mentions
- Influx of FDA-Approved Novel Therapies Changing Gynecologic Oncology CareMarch 24th, 2025
- Phase 3 Trial of Pembrolizumab Combo in Advanced Ovarian Cancer Raises QuestionsMarch 18th, 2025
Grant Support
- Targeting RNA Polymerase I Transcription Machinery in Chemoresistant Ovarian CancerUNIVERSITY OF VIRGINIA2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: